Distribution of Antigenic Aberration in the Bone Marrow of Acute Leukemia in Complete Remission.
- Author:
Soyoung SHIN
1
;
Jimin KAHNG
;
Myungshin KIM
;
Jihyang LIM
;
Younggoo KIM
;
Kyungja HAN
Author Information
- Publication Type:Original Article ; English Abstract
- Keywords: Aberrant antigen; CD20+/CD34+; Myeloid Ag+/CD19+
- MeSH: Acute Disease; Antigens, CD/*metabolism; Antigens, CD19/metabolism; Antigens, CD20/metabolism; Antigens, CD34/metabolism; Antigens, Differentiation, Myelomonocytic/analysis/metabolism; Bone Marrow Cells/*classification/metabolism; Flow Cytometry; Hematopoietic Stem Cells/classification/metabolism; Humans; Immunophenotyping; Leukemia/*diagnosis/drug therapy; Leukemia, Myeloid, Acute/diagnosis/drug therapy; Neoplasm, Residual; Remission Induction; Tumor Markers, Biological/immunology
- From:The Korean Journal of Laboratory Medicine 2008;28(1):1-7
- CountryRepublic of Korea
- Language:Korean
- Abstract: BACKGROUND: The aberrant, leukemia-associated antigen expression patterns allow us to discriminate leukemic blasts from normal precursor cells. Our major goal was to determine a guideline for the detection of minimal residual disease using CD20+/CD34+ and myeloid Ag+/CD19+ combination in the bone marrow of acute leukemia in complete remission (CR) after chemotherapy. METHODS: Bone marrow samples from 117 patients with acute leukemia in complete remission after chemotherapy and from 22 healthy controls were immunophenotyped by triple staining and measured by flow cytometry. RESULTS: The CD20+/CD34+ cells in the large lymphocyte gate (R1) ranged from 0% to 3.24% (0.8+/-0.82%, P=0.000) in CD20+/CD34+ B-lineage ALL CR (N=31), from 0.03% to 4.2% (0.7+/-0.83%, P=0.000) in CD20-/CD34- B-lineage ALL CR (N=66), from 0.1% to 0.96% (0.45+/-0.32%, P=0.016) in T-ALL CR (N=10), and from 0.02% to 0.48% (0.18+/-0.15%, P=0.776) in AML CR (N=10). The CD13,33+/CD19+ cells in R1 gate ranged from 0% to 2.69% (0.37+/-0.48%, P<0.001) in CD13,33+/CD19+ B-lineage ALL CR (N=31), from 0% to 1.8% (0.31+/-0.28%, P<0.001) in CD13,33-/CD19+B-lineage ALL CR (N=65), from 0.02% to 0.64% (0.29+/-0.22%, P=0.071) in T-ALL CR (N=9), and from 0% to 0.17% (0.07+/-0.09%, P=0.341) in AML CR (N=3). CONCLUSIONS: Using an immunophenotypic method for the detection of early relapse or minimal residual disease of B-lineage ALL bone marrow in CR after chemotherapy, different cutoff values should be applied according to antigen combination and gating. When the proportion of aberrant antigen combination was less than 5% in large lymphocyte gate, the results should be interpreted with caution.
